- Phare
- Validé par KD/KO
Anticorps Polyclonal de lapin anti-SMYD3
SMYD3 Polyclonal Antibody for WB, IHC, IF/ICC, IP, ELISA
Hôte / Isotype
Lapin / IgG
Réactivité testée
Humain, rat, souris
Applications
WB, IHC, IF/ICC, IP, CoIP, ChIP, ELISA
Conjugaison
Non conjugué
N° de cat : 12011-1-AP
Synonymes
Galerie de données de validation
Applications testées
| Résultats positifs en WB | tissu cérébral de souris, cellules COLO 320, cellules HeLa, cellules HepG2 | 
| Résultats positifs en IP | cellules COLO 320 | 
| Résultats positifs en IHC | tissu de cancer du sein humain,  tissu de cancer du côlon humain il est suggéré de démasquer l'antigène avec un tampon de TE buffer pH 9.0; (*) À défaut, 'le démasquage de l'antigène peut être 'effectué avec un tampon citrate pH 6,0. | 
| Résultats positifs en IF/ICC | cellules HEK-293, | 
Dilution recommandée
| Application | Dilution | 
|---|---|
| Western Blot (WB) | WB : 1:500-1:1000 | 
| Immunoprécipitation (IP) | IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate | 
| Immunohistochimie (IHC) | IHC : 1:50-1:500 | 
| Immunofluorescence (IF)/ICC | IF/ICC : 1:50-1:500 | 
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, check data in validation data gallery | |
Applications publiées
| KD/KO | See 2 publications below | 
| WB | See 8 publications below | 
| IHC | See 3 publications below | 
| IF | See 1 publications below | 
| CoIP | See 1 publications below | 
| ChIP | See 2 publications below | 
Informations sur le produit
12011-1-AP cible SMYD3 dans les applications de WB, IHC, IF/ICC, IP, CoIP, ChIP, ELISA et montre une réactivité avec des échantillons Humain, rat, souris
| Réactivité | Humain, rat, souris | 
| Réactivité citée | rat, Humain, souris | 
| Hôte / Isotype | Lapin / IgG | 
| Clonalité | Polyclonal | 
| Type | Anticorps | 
| Immunogène | SMYD3 Protéine recombinante Ag2624 | 
| Nom complet | SET and MYND domain containing 3 | 
| Masse moléculaire calculée | 428aa,49 kDa; 369aa,42 kDa | 
| Poids moléculaire observé | 42-45 kDa | 
| Numéro d’acquisition GenBank | BC031010 | 
| Symbole du gène | SMYD3 | 
| Identification du gène (NCBI) | 64754 | 
| Conjugaison | Non conjugué | 
| Forme | Liquide | 
| Méthode de purification | Purification par affinité contre l'antigène | 
| Tampon de stockage | PBS with 0.02% sodium azide and 50% glycerol | 
| Conditions de stockage | Stocker à -20°C. Stable pendant un an après l'expédition. L'aliquotage n'est pas nécessaire pour le stockage à -20oC Les 20ul contiennent 0,1% de BSA. | 
Informations générales
SMYD3,also name as ZMYND1 and ZNFN3A1, belongs to the histone-lysine methyltransferase family.It is a histone methyltransferase that plays an important role in transcriptional regulation in human carcinogenesis. It can specifically methylate histone H3 at lysine 4 and activate the transcription of a set of downstream genes, including several oncogenes (e.g., N-myc, CrkL, Wnt10b, RIZ and hTERT) and genes involved in the control of cell cycle.(PMID: 20957523). It plays an important role in transcriptional activation as a member of an RNA polymerase complex. SMYD3 is frequently overexpressed in different types of cancer cells. It functions as a coactivator of Era and potentiates Era activity in response to ligand. SMYD3 as a new coactivator for ER-mediated transcription, providing a possible link between SMYD3 overexpression and breast cancer. (PMID: 19509295) The common variable number of tandem repeats polymorphism in SMYD3 is a susceptibility factor for some types of human cancer. (PMID:16155568 ) . SMYD3 exists some isoforms with MV 49, 43 and 30 kDa.
Protocole
| Product Specific Protocols | |
|---|---|
| WB protocol for SMYD3 antibody 12011-1-AP | Download protocol | 
| IHC protocol for SMYD3 antibody 12011-1-AP | Download protocol | 
| IF protocol for SMYD3 antibody 12011-1-AP | Download protocol | 
| IP protocol for SMYD3 antibody 12011-1-AP | Download protocol | 
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols | 
Publications
| Species | Application | Title | 
|---|---|---|
| Acta Pharm Sin B SMYD3-PARP16 axis accelerates unfolded protein response and mediates neointima formation.
 | ||
| Carcinogenesis miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. | ||
| CNS Neurosci Ther Integration of Methylation and Gene Expression Deciphered Candidate Biomarkers DAB2IP and SMYD3 in Delayed Encephalopathy After Carbon Monoxide Poisoning | ||
| Int J Androl Histone methylation is a critical regulator of the abnormal expression of POU5F1 and RASSF1A in testis cancer cell lines. | ||
| Cell Physiol Biochem iTRAQ-Based Proteomic Analysis of Neonatal Kidney from Offspring of Protein Restricted Rats Reveals Abnormalities in Intraflagellar Transport Proteins. | 
Avis
The reviews below have been submitted by verified Proteintech customers who received an incentive for providing their feedback.
| FH Deyong (Verified Customer) (03-11-2022) | It worked well in the HEK293T cells with human SMYD3 overexpression. 
 | 
















